Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma

Leukemia and Lymphoma

Volumn 51, Issue 2, 2010, Pages 236-242

  Corso, Alessandro ^a   Barbarano, Luciana ^b   Mangiacavalli, Silvia ^a   Spriano, Mauro ^c   Alessandrino, Emilio P ^a   Cafro, Anna Maria ^b   Pascutto, Cristiana ^a   Varettoni, Marzia ^a   Bernasconi, Paolo ^a   Grillo, Giovanni ^b   Carella, Angelo M ^c   Montalbetti, Luigi ^d   Lazzarino, Mario ^a   Morra, Enrica ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d BUSTO ARSIZIO HOSPITAL   (Italy)

Author keywords

Bortezomib; DCEP; High dose therapy; Induction therapy; Multiple myeloma; Peripheral stem cell collection

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN;

ABSCESS; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GASTRITIS; HEART ARRHYTHMIA; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOTENSION; INFECTION; INSOMNIA; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYCOSIS; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SEPTIC SHOCK;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CISPLATIN; COMBINED MODALITY THERAPY; CONSTIPATION; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIARRHEA; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 76349087848     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903452826     Document Type: Article

References (45)

1. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
2. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK. High-dose chemotherapy with autologous hemopoietic stem cell transplantation in patients with multiple myeloma. Expert Rev Anticancer Ther 2006;6:343-360.
3. Harousseau JL. Stem cell transplantation in multiple myeloma (0,1, or 2). Curr Opin Oncol 2005;17:93-98.
4. Kyle RA, Rajkumar SV. Multiple myeloma. New Engl J Med 2004;351:1860-1873.
5. Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med 1996;335:91-97.
6. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-793.
7. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.
8. Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992;1:329-341.
9. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favourable variables for rapid engraftment in 225 patients. Blood 1995;85:588-596.
10. Allan DS, Keeney M, Howson-Jan K, et al. Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29:967-972.
11. Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients (4/=70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Hematol 2003;120:413-423.
12. Corso A, Caberlon S, Pagnucco G, et al. Blood stem cell collections in multiple myeloma: definition of a scoring system. Bone Marrow Transplant 2000;26:283-286.
13. Alexanian R, Weber D, Giralt S, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001;27:1037-1043.
14. Lahuerta JJ, Mateos MV, Martínez-López J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008;26:5775-5782.
15. Nadal E, Giné E, Bladé J, et al. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant 2004;33:61-64.
16. O'Shea D, Giles C, Terpos E, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-center experience in 211 patients. Bone Marrow Transplant 2006;37:731-737.
17. Van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007;92:1399-1406.
18. Richardson PG, Sonneveld P, Schuster MW, et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New Engl J Med 2005; 352:2487-2498.
19. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110: 3557-3560.
20. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929-934.
21. Jagannath S, Barlogie B, Berenson JR, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol 2008;143:537-540.
22. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776-783.
23. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006;91:1498-1505.
24. Rosiñol L, Oriol A, Mateos MV, et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007;25: 4452-4458.
25. Harousseau JL, Mathiot C, Attal M, et al. Valcade/ dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 Trial. Blood 2007;101(Suppl. 1): (Abstract 450).
26. Jakubowiak A, Kendall T, Al-Zoubi A, et al. Initial treatment with Bortezomib (Velcade1), Doxil1, and dexamethasone (VDD) is superior to thalidomide and dexamethasone (TD) as initial therapy prior to autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Blood 2008; 112(Suppl. 1): (Abstract 3713).
27. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005;129:755-762.
28. Popat R, Oakervee HE, Curry N, et al. Long-term follow-up of PAD for untreated multiple myeloma. Haematologica 2007;92(Suppl. 2): (Abstract Po-725).
29. Sonneveld P, Van der Holt B, Schmidt-Wolf IGH, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs. VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). Haematologica 2009;94(Suppl. 2): (Abstract 0473).
30. Corso A, Arcaini L, Caberlon S, et al. A combination of dexamethasone, cyclophosphamide, etoposide and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. Haematologica 2002;87:1041-1045.
31. Corso A, Mangiacavalli S, Nosari A, et al. Efficacy, toxicity, and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma. Bone Marrow Transplant 2005;36:951-954.
32. Corso A, Barbarano L, Zappasodi P, et al. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma. Haematologica 2004:89:1124-1127.
33. Durie BG, Harousseau JL, Miguel JS, et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473.
34. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. Available from http://ctep.cancer.gov [Accessed 31 March 2003; published date 9 August 2006].
35. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33:86-89. (Pubitemid 20040083)
36. Anderson H, Scarffe JH, Ranson M, et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995;71:326-330.
37. Segeren CM, Sonneveld P, van der Holt B, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999;105:127-130.
38. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Eastern Cooperative Oncology Group Phase III. Clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-436.
39. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-39.
40. Cavo M, DiRaimondo F, Zamagni E, et al. Short term thalidomide incorporated into double autologous stem cell transplantation improves outcomes in comparison with double auto-transplantation for multiple myeloma. J Clin Oncol 2009;27:5001-5007.
41. Macro M, Divine M, Uzunhan Y, et al. Dexamethasone + thalidomide compared to VAD as pre-transplant treatment in newly diagnosed multiple myeloma: a randomized trial. Blood 2006;108(Suppl. 1): (Abstract 22).
42. Rosiñol L, Cibeira MT, Bladé J, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004;89:832-836. (Pubitemid 38981343)
43. Bladé J, Perales M, Rosiñol L, et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 2001;113:422-424.
44. Lacy MQ, Gertz MA, Dispenzieri A, et al. Long-term results of response to therapy, time to progression and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007;82:1179-1184.
45. Kumar S, Giralt S, Stadtmauer EA, et al. Mobilization in Myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009;114:1729-1735.